Relatlimab is approved in a fixed-dose combination with nivolumab as Opdualag for unresectable or metastatic melanoma in adults and pediatric patients aged 12 years or older. FDA describes Opdualag as combining a LAG-3-blocking antibody (relatlimab) with a PD-1-blocking antibody (nivolumab). This approval was granted on March 18, 2022.
Decreases in circulating tumor DNA within 3-4 weeks of immune checkpoint inhibitor therapy were strongly associated with higher response rates and longer survival in patients with unresectable stage III/IV melanoma, according to a multi-institutional retrospective analysis.
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07504796 |
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab |
RECRUITING | PHASE4 |
| NCT06816927 |
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab |
RECRUITING | PHASE2 |
| NCT06683755 |
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT06561386 |
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% |
RECRUITING | PHASE3 |
| NCT06400264 |
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) |
WITHDRAWN | PHASE2 |
| NCT06325683 |
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma |
SUSPENDED | PHASE2 |
| NCT06237920 |
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab |
RECRUITING | PHASE2 |
| NCT06029270 |
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer |
RECRUITING | PHASE2 |
| NCT05987241 |
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study |
RECRUITING | PHASE2/PHASE3 |
| NCT05704647 |
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases |
RECRUITING | PHASE2 |
